Pegfilgrastim-fpgk - Biologic Drug Details

Summary for pegfilgrastim-fpgk

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2

Pharmacology for pegfilgrastim-fpgk

Physiological Effect	Increased Myeloid Cell Production
Established Pharmacologic Class	Leukocyte Growth Factor
Chemical Structure	Granulocyte Colony-Stimulating Factor Granulocyte-Macrophage Colony-Stimulating Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pegfilgrastim-fpgk Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pegfilgrastim-fpgk Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for pegfilgrastim-fpgk Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Pegfilgrastim-fpgk

Last updated: March 12, 2026

What is pegfilgrastim-fpgk?

Pegfilgrastim-fpgk is a biosimilar version of Neulasta (originally pegfilgrastim), used primarily to reduce the incidence and duration of febrile neutropenia in patients undergoing chemotherapy. It employs PEGylation to extend its half-life, allowing for less frequent dosing. Approved by the FDA in December 2022, pegfilgrastim-fpgk is manufactured by Coherus BioSciences under the brand name Udenyca (biosimilar) with the same active ingredient.

What are the key market drivers?

1. Growing prevalence of cancer:
The global cancer burden reaches approximately 19.3 million new cases annually, with hematologic and solid tumors accounting for the majority. This expands demand for supportive care drugs like pegfilgrastim-fpgk.

2. Advances in chemotherapy protocols:
More aggressive treatment regimens increase the risk of neutropenia. Biosimilars provide cost-effective options, stimulating uptake.

3. Cost containment policies:
Healthcare systems, especially in the US, Europe, and emerging markets, favor biosimilars to reduce expenditures. Lower prices foster higher utilization.

4. Regulatory clarity and approvals:
Clear pathways for biosimilar approval in major markets, including the US, EU, and Japan, accelerate entry and adoption.

5. Patent expiration of reference biologics:
The expiration of Neulasta's patent in 2021 opened the market for biosimilar entrants like pegfilgrastim-fpgk, increasing competition.

How does the competitive landscape look?

Major players include:

Manufacturer	Product name	Year of FDA approval	Pricing strategy	Market share (2022)	Notes
Coherus BioSciences	Udenyca	Dec 2022	Discounted biosimilar pricing	~20%	First biosimilar approved in US for this reference biologic
Amgen (original)	Neulasta	2002	Premium pricing	>50% (pre-patent expiry)	Dominant until patent expiry
Mylan/Biocon (Sandoz)	Filgrastim-sndz, Zarxio	2015 (filgrastim)	Low-cost bioslimilar	Growing	Focused on cost-sensitive markets
Samsung Bioepis / Biogen	Onpro and others	2018–2022	Competitive pricing	Increasing	Expanding global reach

Market share estimates:

• Biosimilar pegfilgrastims hold an estimated 15-30% share in US supportive care market as of 2022, rising with broader adoption.

Market size and financial outlook

Market size estimates (2022):

Region	Market size (USD billion)	CAGR (2022–2027)	Notes
North America	2.8	12%	Large base, high biosimilar adoption
Europe	1.5	10%	Favorable biosimilar policies
Asia-Pacific	0.9	14%	Rapid growth, expanding healthcare infrastructure
Rest of World	0.4	9%	Less penetration, price sensitivity

Projection:
The biosimilar segment for pegfilgrastim is expected to reach USD 1.5 billion globally by 2027, with North America leading due to high adoption rates.

Revenue contributions from pegfilgrastim-fpgk (Coherus):

• Launch Year (2022): Estimated USD 50 million in the US
• 2023-2025: Anticipated growth at CAGR 15-20%
• 2027: Projected USD 200-300 million globally

Pricing assumptions and reimbursement

Pricing:
Pegfilgrastim biosimilars typically price 15-30% below the reference biologic, driven by competition. Coherus initially set Udenyca at about 20% discount.

Reimbursement:
In the US, Medicare and private insurers increasingly prefer biosimilar cost savings, leading to higher reimbursement rates and higher adoption rates.

Regulatory and policy influence

• FDA: Fast-track pathways for biosimilars fostered approvals. Sandoz and Biogen have multiple biosimilars in pipeline.
• EU: Puts emphasis on interchangeability, boosting biosimilar market penetration.
• Emerging markets: Slower adoption due to pricing and regulatory hurdles but expanding due to cost pressures.

Limitations and future risks

• Patent litigations: Ongoing patent disputes could delay market entry for new biosimilars.
• Market saturation: High penetration levels may slow growth.
• Physician and patient acceptance: Skepticism toward biosimilars may hamper uptake.
• Pricing pressure: Increased competition can lead to reduced prices.

Key financial considerations

• Gross margins: Estimated 50-60% for pegfilgrastim biosimilars.
• Market penetration: Achieving 30% in North America by 2025.
• Pricing trend: Expect annual price declines of 3-5% as market matures.

Conclusion

Pegfilgrastim-fpgk’s market trajectory depends on biosimilar adoption, regulatory landscape, and competitive dynamics. It is positioned to capture increasing share as biosimilar preference strengthens globally, with revenue growth driven by cost and policy factors.

---

Key Takeaways

• The biosimilar market for pegfilgrastim is expanding, driven by patent expiries, cost savings policies, and new approvals.
• US and Europe lead with adoption rates approaching 30% of the supportive care market by 2025.
• Revenue in the global biosimilar pegfilgrastim segment is projected to reach USD 1.5 billion by 2027.
• Competitive pricing and reimbursement strategies are critical for market share growth.
• Ongoing patent disputes and physician acceptance remain notable risks.

---

FAQs

1. How does pegfilgrastim-fpgk compare to the original pegfilgrastim in terms of efficacy?
It has demonstrated biosimilarity in pharmacokinetics, pharmacodynamics, safety, and efficacy through FDA approval data, matching the original biologic.

2. What are the barriers to biosimilar adoption?
Physician skepticism, regulatory approval delays, and price sensitivities in some markets slow adoption rates.

3. How will pricing evolve for pegfilgrastim biosimilars?
Prices are expected to decrease by 3-5% annually as competition intensifies and market penetration increases.

4. Which regions are expanding biosimilar use fastest?
North America and Europe lead adoption due to supportive policies, with Asia-Pacific experiencing rapid growth.

5. What is the longevity outlook for pegfilgrastim biosimilars?
Patent protections for original biologics expire, enabling biosimilar entry through 2025–2030; market growth will likely plateau as competition stabilizes.

---

References

[1] Food and Drug Administration. (2022). U.S. approves first biosimilar pegfilgrastim.

[2] IQVIA. (2022). The global biologics market report.

[3] Sandoz. (2023). Biosimilar pegfilgrastim: Market entry and policy overview.

[4] European Medicines Agency. (2022). Biosimilar medicines: Market data and approval pathways.

[5] Coherus BioSciences. (2023). Udenyca marketing and financial strategy.